Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2015 1
2017 2
2019 1
2020 1
2022 3
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Results by year

Filters applied: . Clear all
Page 1
The paradox of Myeloid Leukemia associated with Down syndrome.
Gupte A, Al-Antary ET, Edwards H, Ravindranath Y, Ge Y, Taub JW. Gupte A, et al. Biochem Pharmacol. 2022 Jul;201:115046. doi: 10.1016/j.bcp.2022.115046. Epub 2022 Apr 26. Biochem Pharmacol. 2022. PMID: 35483417 Review.
Various other mutations in genes encoding cohesin, epigenetic regulators and RAS pathway can result in subsequent progression to Myeloid Leukemia associated with Down Syndrome (ML-DS). The striking paradoxical feature in the Down syndrome …
Various other mutations in genes encoding cohesin, epigenetic regulators and RAS pathway can result in subsequent progression to Myeloid …
Predispositions to Leukemia in Down Syndrome and Other Hereditary Disorders.
Saida S. Saida S. Curr Treat Options Oncol. 2017 Jul;18(7):41. doi: 10.1007/s11864-017-0485-x. Curr Treat Options Oncol. 2017. PMID: 28580501 Review.
These predispositions to cancer syndromes can be attributed to DNA repair/genetic instability, RAS pathway dysfunction, bone marrow failure, telomeropathies, immunodeficiencies, transcription factor abnormalities, pure familial leukemia, and aneuploidy. We focus especially on acu …
These predispositions to cancer syndromes can be attributed to DNA repair/genetic instability, RAS pathway dysfunction, bone marrow failure, …
Survival outcomes of children with relapsed or refractory myeloid leukemia associated with Down syndrome.
Raghuram N, Hasegawa D, Nakashima K, Rahman S, Antoniou E, Skajaa T, Merli P, Verma A, Rabin KR, Aftandilian C, Kotecha RS, Cheuk D, Jahnukainen K, Kolenova A, Balwierz W, Norton A, O'Brien M, Cellot S, Chopek A, Arad-Cohen N, Goemans B, Rojas-Vasquez M, Ariffin H, Bartram J, Kolb EA, Locatelli F, Klusmann JH, Hasle H, McGuire B, Hasnain A, Sung L, Hitzler J. Raghuram N, et al. Blood Adv. 2023 Nov 14;7(21):6532-6539. doi: 10.1182/bloodadvances.2022009381. Blood Adv. 2023. PMID: 36735769 Free PMC article.
Germline GATA1s-generating mutations predispose to leukemia with acquired trisomy 21 and Down syndrome-like phenotype.
Hasle H, Kline RM, Kjeldsen E, Nik-Abdul-Rashid NF, Bhojwani D, Verboon JM, DiTroia SP, Chao KR, Raaschou-Jensen K, Palle J, Zwaan CM, Nyvold CG, Sankaran VG, Cantor AB. Hasle H, et al. Blood. 2022 May 26;139(21):3159-3165. doi: 10.1182/blood.2021011463. Blood. 2022. PMID: 34758059 Free PMC article.
All evaluable leukemias had acquired trisomy 21 or tetrasomy 21. The leukemia characteristics overlapped with those of myeloid leukemia associated with Down syndrome, including age of onset at younger than 4 years, unique immunophenotype, …
All evaluable leukemias had acquired trisomy 21 or tetrasomy 21. The leukemia characteristics overlapped with those of myeloid leu …
Therapy reduction in patients with Down syndrome and myeloid leukemia: the international ML-DS 2006 trial.
Uffmann M, Rasche M, Zimmermann M, von Neuhoff C, Creutzig U, Dworzak M, Scheffers L, Hasle H, Zwaan CM, Reinhardt D, Klusmann JH. Uffmann M, et al. Blood. 2017 Jun 22;129(25):3314-3321. doi: 10.1182/blood-2017-01-765057. Epub 2017 Apr 11. Blood. 2017. PMID: 28400376 Free article. Clinical Trial.
Children with myeloid leukemia associated with Down syndrome (ML-DS) have superior outcome compared with non-DS patients, but suffer from higher constitutional cytotoxic drug susceptibility. ...
Children with myeloid leukemia associated with Down syndrome (ML-DS) have superior outcome compare …
Highly sensitive detection of GATA1 mutations in patients with myeloid leukemia associated with Down syndrome by combining Sanger and targeted next generation sequencing.
Terui K, Toki T, Taga T, Iwamoto S, Miyamura T, Hasegawa D, Moritake H, Hama A, Nakashima K, Kanezaki R, Kudo K, Saito AM, Horibe K, Adachi S, Tomizawa D, Ito E. Terui K, et al. Genes Chromosomes Cancer. 2020 Mar;59(3):160-167. doi: 10.1002/gcc.22816. Epub 2019 Oct 21. Genes Chromosomes Cancer. 2020. PMID: 31606922
Myeloid leukemia associated with Down syndrome (ML-DS) is characterized by a predominance of acute megakaryoblastic leukemia, the presence of GATA1 mutations and a favorable outcome. ...
Myeloid leukemia associated with Down syndrome (ML-DS) is characterized by a predominance of acute …
A phase III clinical trial evaluating efficacy and safety of minimal residual disease-based risk stratification for children with acute myeloid leukemia, incorporating a randomized study of gemtuzumab ozogamicin in combination with post-induction chemotherapy for non-low-risk patients (JPLSG-AML-20).
Tomizawa D, Tsujimoto SI, Tanaka S, Matsubayashi J, Aoki T, Iwamoto S, Hasegawa D, Nagai K, Nakashima K, Kawaguchi K, Deguchi T, Kiyokawa N, Ohki K, Hiramatsu H, Shiba N, Terui K, Saito AM, Kato M, Taga T, Koshinaga T, Adachi S. Tomizawa D, et al. Jpn J Clin Oncol. 2022 Oct 6;52(10):1225-1231. doi: 10.1093/jjco/hyac105. Jpn J Clin Oncol. 2022. PMID: 35809896 Clinical Trial.
The purpose of this study is to establish a treatment with appropriate intensity for children (<16 years old at diagnosis) with de novo acute myeloid leukemia (excluding acute promyelocytic leukemia and myeloid leukemia associated with Down …
The purpose of this study is to establish a treatment with appropriate intensity for children (<16 years old at diagnosis) with de novo a …
Survival outcomes of myeloid leukemia associated with Down syndrome and de novo acute myeloid leukemia in children: Experience from a single tertiary center in Thailand.
Songthawee N, Sripornsawan P, Chavananon S, Kittivisuit S, McNeil EB, Chotsampancharoen T. Songthawee N, et al. Pediatr Hematol Oncol. 2024;41(2):150-162. doi: 10.1080/08880018.2023.2286970. Epub 2024 Feb 10. Pediatr Hematol Oncol. 2024. PMID: 38013232
Few studies have reported the survival outcomes of myeloid leukemia associated with Down syndrome (DS) in resource-limited countries. ...
Few studies have reported the survival outcomes of myeloid leukemia associated with Down syndrome …
Favorable survival maintained in children who have myeloid leukemia associated with Down syndrome using reduced-dose chemotherapy on Children's Oncology Group trial A2971: a report from the Children's Oncology Group.
Sorrell AD, Alonzo TA, Hilden JM, Gerbing RB, Loew TW, Hathaway L, Barnard D, Taub JW, Ravindranath Y, Smith FO, Arceci RJ, Woods WG, Gamis AS. Sorrell AD, et al. Cancer. 2012 Oct 1;118(19):4806-14. doi: 10.1002/cncr.27484. Epub 2012 Mar 5. Cancer. 2012. PMID: 22392565 Free PMC article. Clinical Trial.
BACKGROUND: Children who are treated for myeloid leukemia associated with Down syndrome (DS) experience superior survival compared with children who have myeloid leukemia without DS. ...
BACKGROUND: Children who are treated for myeloid leukemia associated with Down syndrome (DS) exper …
Extensive placental choriovascular infiltration by maturing myeloid cells in down syndrome-associated transient abnormal myelopoiesis.
Ravishankar S, Hoffman L, Lertsburapa T, Welch J, Treaba D, De Paepe ME. Ravishankar S, et al. Pediatr Dev Pathol. 2015 May-Jun;18(3):231-6. doi: 10.2350/14-11-1575-CR.1. Epub 2015 Jan 14. Pediatr Dev Pathol. 2015. PMID: 25587735
Approximately 20%-30% of TAM survivors are at risk of development of acute myeloid leukemia (myeloid leukemia associated with Down syndrome, ML-DS). We report unusual placental findings in a female infant with trisomy 21 born at 38 weeks …
Approximately 20%-30% of TAM survivors are at risk of development of acute myeloid leukemia (myeloid leukemia associated …